Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION

v3.21.4
SEGMENT INFORMATION
 12 Months Ended
Oct. 31, 2021
Segment Reporting [Abstract]  
SEGMENT INFORMATION

9.    SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) our legacy Cancer Diagnostics activities and (v) our legacy Patent Licensing activities. The following represents selected financial information for our segments for the years ended October 31, 2021 and 2020:

 

 

ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

    Year Ended October 31,  
    2021     2020  
Net income/(loss):                
CAR-T Therapeutics   $ (5,672,622 )   $ (2,241,443 )
Cancer Vaccines     (4,558,811 )     (828,136 )
Anti-Viral Therapeutics     (2,927,979 )     (1,168,969 )
Cancer Diagnostics     (78,067 )     (5,836,594 )
Patent Licensing     109,556       (17,221 )
Total   $ (13,127,923 )   $ (10,092,363 )
                 
Total operating costs and expenses   $ 13,648,192     $ 9,978,202  
Less non-cash share-based compensation     (8,058,078 )     (4,137,460 )

Operating costs and expenses excluding non-cash share-based compensation

   $ 5,590,114     $ 5,840,742  
                 

Operating costs and expenses excluding non-cash share based compensation:

                
CAR-T Therapeutics   $ 2,421,487     $ 1,141,542  
Cancer Vaccines     1,641,977       365,681  
Anti-Viral Therapeutics     1,080,279       739,140  
Cancer Diagnostics     49,170       3,581,377  
Patent Licensing     397,201       13,002  
Total   $ 5,590,114     $ 5,840,742  

 

    October 31,  
    2021     2020  
Total assets:                
CAR-T Therapeutics   $ 15,067,933     $ 2,988,124  
Cancer Vaccines     13,276,518       946,923  
Anti-Viral Therapeutics     7,368,214       2,464,361  
Cancer Diagnostics     391,618       2,869,529  
Patent Licensing     153,121       184,027  
Total   $ 36,257,404     $ 9,452,964  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $512,500 and inventor royalties, contingent legal fees, litigation and licensing expense of $385,002, for the year ended October 31, 2021 were solely related to our patent licensing segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.